A real-world comparison of relapse rates, healthcare costs and resource use among patients with multiple sclerosis newly initiating subcutaneous interferon beta-1a versus oral disease-modifying drugs.
James D BowenChris M KozmaMegan M GrossoAmy L PhillipsPublished in: Multiple sclerosis journal - experimental, translational and clinical (2018)
Patients initiating sc IFNβ-1a had better relapse outcomes v. teriflunomide, and lower all-cause costs v. fingolimod.